# Norepinephrine-targeted Therapy for Action Control in Parkinson Disease

> **NCT03115827** · PHASE4 · COMPLETED · sponsor: **Vanderbilt University Medical Center** · enrollment: 15 (actual)

## Conditions studied

- Parkinson Disease

## Interventions

- **DRUG:** Droxidopa
- **DRUG:** Carbidopa

## Key facts

- **NCT ID:** NCT03115827
- **Lead sponsor:** Vanderbilt University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-04-18
- **Primary completion:** 2018-12-21
- **Final completion:** 2018-12-21
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2020-01-27

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03115827

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03115827, "Norepinephrine-targeted Therapy for Action Control in Parkinson Disease". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03115827. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*